Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells $31,410.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total value of $31,410.00. Following the completion of the transaction, the director now owns 74,438 shares of the company’s stock, valued at $519,577.24. The trade was a 5.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Health Catalyst Trading Down 0.1 %

NASDAQ:HCAT traded down $0.01 during trading hours on Friday, hitting $7.08. 560,524 shares of the stock were exchanged, compared to its average volume of 562,055. The company’s 50 day moving average is $7.99 and its two-hundred day moving average is $7.46. The company has a market capitalization of $430.80 million, a P/E ratio of -5.24 and a beta of 1.31. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the prior year, the business earned ($0.22) EPS. Health Catalyst’s revenue was up 3.5% on a year-over-year basis. On average, sell-side analysts anticipate that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently bought and sold shares of HCAT. Principal Financial Group Inc. boosted its position in shares of Health Catalyst by 6.9% in the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after purchasing an additional 1,907 shares during the last quarter. Rhumbline Advisers boosted its stake in Health Catalyst by 9.1% during the 2nd quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock worth $582,000 after acquiring an additional 7,589 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in Health Catalyst by 276.3% in the second quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock worth $1,365,000 after purchasing an additional 156,908 shares during the period. Acadian Asset Management LLC boosted its position in shares of Health Catalyst by 1.3% during the second quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock worth $4,690,000 after purchasing an additional 9,697 shares in the last quarter. Finally, ClariVest Asset Management LLC lifted its holdings in Health Catalyst by 1.2% during the second quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock worth $1,825,000 after acquiring an additional 3,302 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Analyst Ratings Changes

HCAT has been the subject of a number of recent research reports. Royal Bank of Canada increased their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Citigroup increased their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Piper Sandler restated an “overweight” rating and issued a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Finally, Evercore ISI lifted their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Health Catalyst has an average rating of “Moderate Buy” and a consensus price target of $11.79.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.